Announcement
16.12.2011

NeuroSeach A/S (NEUR) has received information from Porter Orlin LLC, New York,
that the company has increased its voting rights in NeuroSearch A/S attached to
shares owned by other companies.

Hereafter, Porter Orlin LLC administers a total of 2,481,804 shares of DKK 20
nominal value corresponding to a total ownership and voting rights of 10.11%.

Patrik Dahlen
CEO

Contact person
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097


About NeuroSearch
NeuroSearch A/S (NEUR) is a European-based biopharmaceutical company listed on
NASDAQ OMX Copenhagen A/S and specialising in central nervous system (CNS)
disorders. The vision is to develop NeuroSearch into a profitable specialty
pharmaceutical company. The strategy is primarily to complete the development
and subsequently to market Huntexil®, a unique drug in clinical Phase III for
the treatment of the motor symptoms of Huntington’s disease.
Among discontinuing activities, NeuroSearch also has a portfolio of assets for
outlicensing or divestment. This includes tesofensine which has shown
outstanding efficacy in the treatment of obesity, the Integrative Screening
Process (ISP), which is a proprietary systems biology approach, as well as a
broad range of ion channel technologies and patented compounds identified as
ion channel modulators.

Fonds.31-11 - Major shareholder - Porter Orlin LLC - UK.pdf